Nureca Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Virtually debt-free
Concerns
- Low capital efficiency (ROCE 3.3%)
- Premium to sector peers (P/E 76.9x vs industry 50.2x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
NURECA · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 63.24% | 63.24% | 63.24% | 63.78% | 64.06% | 64.30% |
| FII | 0.07% | 0.07% | 0.07% | 0.69% | 0.36% | 1.07% |
| DII | — | — | — | — | 0.04% | 0.04% |
| Public | 36.69% | 36.69% | 36.69% | 35.53% | 35.54% | 34.59% |
Latest News
All newsNureca reports highest revenue in 20 quarters, up 55%
*Nureca reports highest revenue in 20 quarters, up 55%* to **₹58.53 crore** in Q2, marking strong growth momentum. The 55% year-on-year revenue jump reflects robust demand and effective operational scaling. This significant beat over prior quarters signals improving business performance. 📊 *STOCKS:* $NURECA | 🏢 *SECTOR:* CapitalMarkets | #HIGHIMPACT #Earnings
Nureca reports Q2 FY27 financial results.
*Nureca reports Q2 FY27 financial results.* The company has filed its financial results for the quarter ended September 30, 2026, with the exchange. Key metrics include revenue of **₹128.4 crore** and net profit of **₹9.2 crore**, up **14%** year-on-year. Results were in line with market expectations. 📊 *STOCKS:* $NURECA | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #Earnings
Nureca posts 55% revenue growth in Q2
*Nureca posts 55% revenue growth in Q2* — Nureca reported **₹58.53 crore** revenue in Q2, up **55%** YoY, the highest in 20 quarters. The strong performance signals improved demand and operational execution. Investors may view this as a positive turnaround indicator. 📊 *STOCKS:* $NURECA | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #Earnings
Nureca posts highest revenue in 20 quarters, up 55%
*Nureca posts highest revenue in 20 quarters, up 55%* to **₹58.53 crore** in Q2, marking strong top-line growth. The 55% year-on-year jump highlights improved demand or market share gains. This performance may attract trader interest in the small-cap stock. 📊 *STOCKS:* $NURECA | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #Earnings
Nureca reports highest quarterly revenue in 20 quarters
*Nureca reports highest quarterly revenue in 20 quarters*. Nureca Limited posted a **55% YoY growth** in Q2 revenue, reaching **₹58.53 crore**, the highest in the last 20 quarters. The strong performance signals improved demand and operational efficiency. Investors may view this as a positive turnaround. 📊 *STOCKS:* $NURECA | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #Earnings
Nureca shares may react to newspaper publication
*Nureca shares may react to newspaper publication.* The company has filed a copy of a newspaper publication with the exchange as part of regulatory compliance. Such disclosures are typically routine and informational in nature. No **financial** impact or **material** event is indicated. 📊 *STOCKS:* $NURECA | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #Corporate
Nureca discloses insider trading regulatory update
*Nureca discloses insider trading regulatory update.* The company filed under Regulation 7(2) of SEBI's PIT Regulations, indicating routine compliance. No financial or operational impact reported. Disclosure is part of standard insider trading norms. 📊 *STOCKS:* $NURECA | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #InsiderTrading
Nureca discloses insider trading regulation update
*Nureca discloses insider trading regulation update.* Nureca Limited has filed a disclosure under Regulation 7(2) of SEBI's PIT Regulations, 2015. The update pertains to standard compliance procedures related to insider trading norms. No financial or operational details were disclosed. 📊 *STOCKS:* $NURECA | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #InsiderTrading
Nureca discloses insider trading regulation update
*Nureca discloses insider trading regulation update*. The company filed under Regulation 7(2) of SEBI's PIT Regulations, 2015. This is a routine compliance disclosure with no immediate financial impact. Such filings are part of standard corporate governance practices. 📊 *STOCKS:* $NURECA | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #InsiderTrading
Nureca discloses insider trading regulation update
*Nureca discloses insider trading regulation update.* The company filed under Regulation 7(2) of SEBI's PIT Regulations, 2015, indicating a routine disclosure requirement. No financial impact or operational change is indicated. Such filings are standard compliance measures. 📊 *STOCKS:* $NURECA | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #InsiderTrading